Dapaglifozin on Albuminuria in Chronic Kidney Disease Patients with FabrY Disease: The DEFY Study Design and Protocol
Fabry disease (FD) is a rare genetic disorder caused by a deficiency in the α-galactosidase A enzyme, which results in the globotriaosylceramide accumulation in many organs, including the kidneys. Nephropathy is a major FD complication that can progress to end-stage renal disease if not treated earl...
Main Authors: | Yuri Battaglia, Francesca Bulighin, Luigi Zerbinati, Nicola Vitturi, Giacomo Marchi, Gianni Carraro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/12/11/3689 |
Similar Items
-
ACE inhibitor angioedema: characterization and treatment versus non-ACE angioedema in acute hospitalized patients
by: David S. Weisman, et al.
Published: (2020-01-01) -
Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study
by: Dorien M. C. F. Sluijsmans, et al.
Published: (2021-05-01) -
Renoprotective effect of pentoxifylline in advanced chronic kidney disease
by: Chih-Chin Kao
Published: (2015-01-01) -
Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?
by: Elena Raccuglia, et al.
Published: (2009-11-01) -
Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)